UK Markets closed
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • FTSE 250

    19,835.95
    +146.93 (+0.75%)
     
  • AIM

    956.64
    +9.47 (+1.00%)
     
  • GBP/EUR

    1.1822
    +0.0040 (+0.34%)
     
  • GBP/USD

    1.2496
    +0.0021 (+0.1674%)
     
  • BTC-GBP

    23,492.43
    -736.12 (-3.04%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • S&P 500

    3,901.36
    +0.57 (+0.01%)
     
  • DOW

    31,261.90
    +8.77 (+0.03%)
     
  • CRUDE OIL

    112.70
    +0.49 (+0.44%)
     
  • GOLD FUTURES

    1,845.10
    +3.90 (+0.21%)
     
  • NIKKEI 225

    26,739.03
    +336.19 (+1.27%)
     
  • HANG SENG

    20,717.24
    +596.56 (+2.96%)
     
  • DAX

    13,981.91
    +99.61 (+0.72%)
     
  • CAC 40

    6,285.24
    +12.53 (+0.20%)
     

Novo Nordisk Settles Securities Lawsuit in Denmark

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Sam Boughedda

Investing.com — Novo Nordisk A/S (NYSE:NVO) said Friday that it has settled a securities lawsuit in Denmark.

Shares of Novo fell 3% in midday trading.

The company said the settlement contained no admission of liability, wrongdoing or responsibility and Novo Nordisk is not making any payment.

The 2019 lawsuit alleged the company made misleading statements and did not make appropriate disclosures regarding its insulin business in the United States.

The lawsuit was filed by several shareholders claiming compensation worth 11.785 billion Danish crowns or approximately $1.75 billion.

At the time, Novo said it "disagrees with the allegations and is prepared to defend the company in this matter."

Related Articles

Novo Nordisk Settles Securities Lawsuit in Denmark

S&P 500 Falls After Bank Earnings Fail to Impress

Nearly 90% of big US meat plants had COVID-19 cases in pandemic’s first year - data

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting